Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Tonix Pharm Holdings (TNXP)

$10.98 -1.45 (-11.67%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	198.15M
Revenue (ttm)	13.11M
Net Income (ttm)	-124.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-946.00%
Debt to Equity Ratio	0.00

Volume	697,161
Avg Vol	539,526
Day's Range	N/A - N/A
Shares Out	15.94M
Stochastic %K	67%
Beta	1.64
Analysts	Strong Sell
Price Target	$42.20

Company Profile

Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company d...

Industry: Biotechnology

Sector: Healthcare

Phone: 862 799 8599

Website: www.tonixpharma.com

Address:

200 Connell Drive, Suite 3100, Berkeley Heights, United States

IBIO_KEVINTL Jul. 20 at 9:24 PM

$TNXP SSR tomorrow

0 · Reply

IBIO_KEVINTL Jul. 20 at 9:23 PM

$TNXP

0 · Reply

Allstar81 Jul. 20 at 9:00 PM

$TNXP Short Sale Restriction tomorrow?

0 · Reply

MalwareOfMarkets Jul. 20 at 8:48 PM

$TNXP good deals, good sales going on, hiring more employees, lets see after er

0 · Reply

JuggernautRaider Jul. 20 at 8:31 PM

$TNXP brother 💪 💊 🇺🇸 This 💊 🇺🇸 🎇 Is a winner 🇺🇸 💥 🤯

0 · Reply

gc358 Jul. 20 at 8:31 PM

$TNXP didn’t take long to take it into 10s. Don’t know what will stop the bleeding at this point. Shorts hitting it daily.

0 · Reply

TheUnmaker Jul. 20 at 8:25 PM

$TNXP These days are brutal - LMAO

1 · Reply

Sammy2425 Jul. 20 at 8:15 PM

$TNXP Seth always with the PUMP before the breast feeding. Get ready longs. Those 50 sales Rep won’t work for free. Gotta keep the lights on.

0 · Reply

jeni1988 Jul. 20 at 7:58 PM

$TNXP 🤮🤮🤮🤮🤮🤮🤮

0 · Reply

ByBi Jul. 20 at 7:54 PM

$TNXP X 1000

0 · Reply

Tonix Pharmaceuticals Holding Slides: Investor presentation

Jul 15, 2026, 9:05 AM EDT - 5 days ago

Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models

2026-07-13T11:15:17.000Z - 7 days ago

Tonix Pharmaceuticals announces managed Medicare agreement for Tonmya

Jul 13, 2026, 7:00 AM EDT - 7 days ago

Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®

Jul 1, 2026, 8:00 AM EDT - 19 days ago

Tonix Pharmaceuticals Holding Slides: Investor presentation

2026-06-29T11:40:14.000Z - 21 days ago

Tonix Pharmaceuticals enrolls first patient in HORIZON study

Jun 29, 2026, 7:25 AM EDT - 21 days ago

Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)

2026-06-24T20:36:04.000Z - 26 days ago

Tonix Pharmaceuticals initiated with a Strong Buy at Raymond James

Jun 15, 2026, 7:00 AM EDT - 5 weeks ago

Tonix Pharmaceuticals Holding Slides: Investor presentation

Jun 11, 2026, 7:00 AM EDT - 5 weeks ago

Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026

2026-06-08T11:14:39.000Z - 6 weeks ago

Tonix Pharmaceuticals secures second commercial agreement for Tonmya

Jun 8, 2026, 7:00 AM EDT - 6 weeks ago

Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives

Jun 1, 2026, 7:00 AM EDT - 7 weeks ago

Tonix Pharmaceuticals Holding Slides: Investor presentation

2026-05-28T21:29:12.000Z - 7 weeks ago

Tonix presents data from analysis of opioid use in adults with fibromyalgia

May 28, 2026, 4:30 PM EDT - 7 weeks ago

Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

2026-05-27T13:00:38.000Z - 7 weeks ago

Tonix Pharmaceuticals publishes TNX-1500 data in Journal of Clinical Immunology

May 27, 2026, 7:00 AM EDT - 7 weeks ago

Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology

May 27, 2026, 7:00 AM EDT - 7 weeks ago

Tonix Pharmaceuticals Holding Slides: Investor presentation

2026-05-26T11:57:59.000Z - 7 weeks ago

Tonix Pharmaceuticals presents data from analysis of adults with fibromyalgia

May 26, 2026, 7:00 AM EDT - 7 weeks ago

Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting

May 19, 2026, 1:35 PM EDT - 2 months ago

Tonix Pharmaceuticals Holding Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 17, 2026, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals Holding Slides: 2nd Richard Slayman Clinical Xenotransplantation Workshop presentation

May 14, 2026, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026

May 12, 2026, 4:30 PM EDT - 2 months ago

Tonix Pharmaceuticals to Participate in Two Investor Conferences in May

2026-05-11T23:47:32.000Z - 2 months ago

Tonix Pharmaceuticals reports Q1 EPS ($2.93) vs. ($2.84) last year

May 11, 2026, 4:30 PM EDT - 2 months ago

Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights

May 11, 2026, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals Holding Quarterly report: Q1 2026

May 11, 2026, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals Holding Earnings release: Q1 2026

2026-05-07T04:37:07.000Z - 2 months ago

Tonix Pharmaceuticals secures commercial payer coverage for Tonmya

May 6, 2026, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients

2026-05-04T09:45:07.000Z - 2 months ago

Tonix Pharmaceuticals initiated with a Buy at TD Cowen

2026-04-29T15:52:42.000Z - 2 months ago

Tonix Pharmaceuticals says on track to initiate Phase 2 study of TNX-4800

Apr 29, 2026, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at Johns Hopkins University

Apr 23, 2026, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026

2026-04-15T11:14:23.000Z - 3 months ago

Tonix Pharmaceuticals publishes Tonmya study data findings

Apr 15, 2026, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development

Apr 7, 2026, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Holding Slides: Investor presentation

2026-03-31T11:25:26.000Z - 3 months ago

Tonix Pharmaceuticals presents TNX-4800 data, to initiate adaptive field study

Mar 31, 2026, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026

Mar 31, 2026, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Holding Slides: Corporate presentation

Mar 30, 2026, 8:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Holding Proxy statement: Proxy filing

2026-03-26T11:30:11.000Z - 4 months ago

Tonix Pharmaceuticals doses first patient in TNX-1900 study

Mar 26, 2026, 7:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain

Mar 24, 2026, 8:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Holding Slides: Conference presentation

Mar 23, 2026, 4:32 PM EDT - 4 months ago

Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026

Mar 20, 2026, 8:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Holding Proxy statement: Proxy filing

Mar 18, 2026, 4:58 PM EDT - 4 months ago

Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026

Mar 17, 2026, 4:35 PM EDT - 4 months ago

Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026

Mar 12, 2026, 5:30 PM EDT - 4 months ago

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Mar 12, 2026, 7:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Holding Earnings release: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Holding Annual report: Q4 2025

Mar 11, 2026, 1:00 PM EDT - 4 months ago

Tonix Pharmaceuticals Holding Transcript: Life Sciences Virtual Investor Forum

2026-03-10T12:36:35.000Z - 4 months ago

Tonix Pharmaceuticals announces presentations on Tonmya

Mar 10, 2026, 8:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia

Mar 9, 2026, 4:30 PM EDT - 4 months ago

Tonix Pharmaceuticals Presented Data on TONMYA™ in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting

Mar 9, 2026, 4:30 PM EDT - 4 months ago

Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting

Mar 9, 2026, 7:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Holding Slides: Investor presentation

2026-03-05T21:50:16.000Z - 4 months ago

Tonix Pharmaceuticals publishes TNX-102 SL data in journal

Mar 5, 2026, 4:15 PM EST - 4 months ago

Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development

Mar 4, 2026, 11:10 AM EST - 4 months ago

Tonix Pharmaceuticals Holding Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 4:30 PM EST - 4 months ago

Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting

2026-03-03T11:06:52.000Z - 4 months ago

Tonix Pharmaceuticals approved to list on Nasdaq Global Select Market

Mar 3, 2026, 6:00 AM EST - 4 months ago

Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market

Feb 25, 2026, 7:00 AM EST - 5 months ago

Tonix Pharmaceuticals to Participate in Two Investor Conferences in March

Jan 30, 2026, 7:00 AM EST - 6 months ago

Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit

Jan 6, 2026, 7:00 AM EST - 6 months ago

Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026

Dec 29, 2025, 7:57 AM EST - 7 months ago

Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering

Dec 29, 2025, 7:45 AM EST - 7 months ago

Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)

Dec 16, 2025, 7:00 AM EST - 7 months ago

Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University

Dec 9, 2025, 7:00 AM EST - 7 months ago

Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel

Nov 24, 2025, 7:00 AM EST - 8 months ago

Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder

Nov 17, 2025, 7:00 AM EST - 8 months ago

Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment

Nov 13, 2025, 10:00 AM EST - 8 months ago

Tonix Pharmaceuticals Holding Transcript: Stifel 2025 Healthcare Conference

Nov 13, 2025, 10:00 AM EST - 8 months ago

Tonix Pharmaceuticals Holding Slides: FY 2025

Nov 10, 2025, 4:15 PM EST - 9 months ago

Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights

Nov 10, 2025, 7:00 AM EST - 9 months ago

Tonix Pharmaceuticals Holding Earnings release: Q3 2025

Nov 10, 2025, 7:00 AM EST - 9 months ago

Tonix Pharmaceuticals Holding Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 9 months ago

Tonix Pharmaceuticals to Participate in the Stifel 2025 Healthcare Conference

Nov 4, 2025, 7:00 AM EST - 9 months ago

Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection

Oct 28, 2025, 7:00 AM EDT - 9 months ago

Tonix Pharmaceuticals Announces Presentation at BIO-Europe 2025

Oct 27, 2025, 7:00 AM EDT - 9 months ago

Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence

Oct 22, 2025, 7:00 AM EDT - 9 months ago

Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix's Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital

Oct 21, 2025, 7:00 AM EDT - 9 months ago

Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence

Oct 17, 2025, 7:00 AM EDT - 9 months ago

Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025

Oct 14, 2025, 7:00 AM EDT - 9 months ago

Tonix Pharmaceuticals Presented an Update on Fc-modified anti-CD40L mAb, TNX-1500, at the 61st Annual Congress of the Japan Society for Transplantation

Oct 9, 2025, 7:00 AM EDT - 10 months ago

Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025

Oct 2, 2025, 7:00 AM EDT - 10 months ago

Tonix Pharmaceuticals Holding Slides: Investor presentation

Sep 30, 2025, 8:30 AM EDT - 10 months ago

Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access

Sep 29, 2025, 7:00 AM EDT - 10 months ago

Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026

Sep 29, 2025, 7:00 AM EDT - 10 months ago

Tonix Pharmaceuticals Holding Slides: Investor presentation

Sep 18, 2025, 8:00 AM EDT - 10 months ago

Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder

Sep 18, 2025, 7:00 AM EDT - 10 months ago

Tonix Pharmaceuticals Holding Slides: Corporate Presentation

Sep 17, 2025, 7:00 AM EDT - 10 months ago

Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800)

IBIO_KEVINTL Jul. 20 at 9:24 PM

$TNXP SSR tomorrow

0 · Reply

IBIO_KEVINTL Jul. 20 at 9:23 PM

$TNXP

0 · Reply

Allstar81 Jul. 20 at 9:00 PM

$TNXP Short Sale Restriction tomorrow?

0 · Reply

MalwareOfMarkets Jul. 20 at 8:48 PM

$TNXP good deals, good sales going on, hiring more employees, lets see after er

0 · Reply

JuggernautRaider Jul. 20 at 8:31 PM

$TNXP brother 💪 💊 🇺🇸 This 💊 🇺🇸 🎇 Is a winner 🇺🇸 💥 🤯

0 · Reply

gc358 Jul. 20 at 8:31 PM

$TNXP didn’t take long to take it into 10s. Don’t know what will stop the bleeding at this point. Shorts hitting it daily.

0 · Reply

TheUnmaker Jul. 20 at 8:25 PM

$TNXP These days are brutal - LMAO

1 · Reply

Sammy2425 Jul. 20 at 8:15 PM

$TNXP Seth always with the PUMP before the breast feeding. Get ready longs. Those 50 sales Rep won’t work for free. Gotta keep the lights on.

0 · Reply

jeni1988 Jul. 20 at 7:58 PM

$TNXP 🤮🤮🤮🤮🤮🤮🤮

0 · Reply

ByBi Jul. 20 at 7:54 PM

$TNXP X 1000

0 · Reply

Sammy2425 Jul. 20 at 7:54 PM

$TNXP 1.00

0 · Reply

modernaproblema Jul. 20 at 7:48 PM

$TNXP did you know that we only have 10,000 less watchers than $SPCX!

1 · Reply

King_of_Bio Jul. 20 at 7:43 PM

$TNXP Sad there are still people pumping this day after day. But hey, keep listening to them. Blind leading the blind.

2 · Reply

Mstrong87 Jul. 20 at 7:31 PM

$TNXP iPad baby showing again little guy. I’m not in this for instant gratification. I know you young kids don’t get that. I’m be day you’ll grow up and become an adult 😂😂🥳🥳🤡🤡🫶🫶

0 · Reply

TOOKPROFITS Jul. 20 at 7:28 PM

$TNXP how much now dunsky

0 · Reply

TOOKPROFITS Jul. 20 at 7:27 PM

$TNXP dunsky

1 · Reply

TOOKPROFITS Jul. 20 at 7:26 PM

$TNXP come on 10s come on 10s

0 · Reply

XP05B18801 Jul. 20 at 7:23 PM

$TNXP The sheep continue to dump their hard earned money into this dog. Sathan has zero respect for you as a stakeholder or your money. Seek therapy.

0 · Reply

Oldmoneycashhoney Jul. 20 at 7:05 PM

$TNXP I actually feel sorry for you bulls. I knew this would happen

0 · Reply

JuggernautRaider Jul. 20 at 7:00 PM

$MAT gonna be a buyer 😋 soon. $TNXP $IMRX $CCCC … soon

0 · Reply

modernaproblema Jul. 20 at 6:44 PM

$TNXP exhausted, but still adding to my position…

3 · Reply

Bobear12 Jul. 20 at 6:34 PM

$TNXP $TNXP this company is lead by Seth and is a Joke. Seth has all the money he will ever need what able the little guy investor? Bo😡

0 · Reply

1.0.0